J. Henderson

Publications12
h-index4
Citations52
Highly Influential Citations2
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Henderson
  • 92 Publications • 9,592 Citations
  • R. Jedwab
  • 50 Publications • 1,681 Citations
  • Dietrich Vollrath
  • 46 Publications • 1,926 Citations
  • D. Gollin
  • 132 Publications • 8,196 Citations
  • Publications
  • Influence
Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis
Systemic Sclerosis (SSc) is a rare fibrotic autoimmune disorder for which no curative treatments currently exist. Metabolic remodelling has recently been implicated in other autoimmune diseases;… Expand
  • 3
  • 2
The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target.
Systemic sclerosis (SSc) is a rare autoimmune disorder characterised by skin fibrosis that often also affects internal organs, eventually resulting in mortality. Although management of the symptoms… Expand
  • 18
Targeting TLRs and the inflammasome in systemic sclerosis
ABSTRACT Systemic sclerosis (SSc) is an idiopathic autoimmune disease characterised by inflammation, vascular problems, cytokine dysregulation and ultimately fibrosis, which accounts for poor… Expand
  • 16
Inflammasome lights up in systemic sclerosis
Systemic sclerosis (SSc) is a pro-fibrotic condition with a poorly understood aetiology. Evidence presented by Artlett et al. in this issue suggests that the microRNA miR-155 is key, with its… Expand
  • 5
  • PDF
Methyl cap binding protein 2: a key epigenetic protein in systemic sclerosis
OBJECTIVE SSc is an autoimmune connective tissue disease that results in skin fibrosis and currently has no effective treatment. Epigenetic modifications have been described and these may be key in… Expand
  • 7
Pharmaceutical development of IPI‐504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer
IPI‐504 (retaspimycin hydrochloride) is an Hsp90 inhibitor that is the subject of multiple clinical trials for the treatment of cancer. IPI‐504 is an aqueous soluble (>200 mg/ml) hydroquinone… Expand
  • 2
Wnt antagonist DKK‐1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a‐3p
Systemic sclerosis is an autoimmune skin disease which is associated with inflammation and resulting skin fibrosis. Myofibroblasts are the key cell type associated with the fibrosis but how they are… Expand
  • 1
State‐of‐the‐art process for the safe synthesis of anticancer drugs
Most cancer drugs are quite potent and represent a potential hazard to chemists conducting their synthesis. Chemical development teams must therefore integrate proper handing techniques for such… Expand
microRNA27a-3p mediates reduction of the Wnt antagonist sFRP-1 in systemic sclerosis.
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease that leads to skin and lung fibrosis. The Wnt pathway is clearly elevated in SSc and is pro-fibrotic via activation of canonical… Expand
A therapy for systemic sclerosis: STAT!
SSc is a rare autoimmune disorder associated with high morbidity and mortality, a consequence of the diffuse fibrosis that targets multiple organs as the disease progresses. Pathogenesis is thought… Expand
...
1
2
...